
MannKind Secures Major FDA Approval for Updated Afrezza Label, Enhancing Dosing Guidance for Patients Transitioning from MDI and Insulin Pump Therapy
FDA Approves Updated Afrezza Label, Marking a Turning Point in Mealtime Insulin TherapyMannKind Corporation has announced a significant regulatory mil...
















































